Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years

Journal of Infectious Diseases

Volumn 213, Issue 12, 2016, Pages 1872-1875

  Tseng, Hung Fu ^a   Harpaz, Rafael ^b   Luo, Yi ^a   Hales, Craig M ^b   Sy, Lina S ^a   Tartof, Sara Y ^a   Bialek, Stephanie ^b   Hechter, Rulin C ^a   Jacobsen, Steven J ^a  

^a KAISER PERMANENTE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adult vaccination; Herpes zoster; Shingles; Varicella zoster virus

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADULT; AGED; AGING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; ELECTRONIC HEALTH RECORD; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HERPES ZOSTER; HUMAN; MALE; PRIORITY JOURNAL; REVACCINATION; REVIEW; TREND STUDY; VACCINATION; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SECONDARY IMMUNIZATION;

HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION, SECONDARY; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; VACCINATION;

EID: 84971001931     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw047     Document Type: Review

References (15)

1. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1-30.
2. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
3. Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015; 60:900-9.
4. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55:1320-8.
5. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087-96.
6. Derose SF, Contreras R, Coleman KJ, Koebnick C, Jacobsen SJ. Race and ethnicity data quality and imputation using U. S. Census data in an integrated health system: The Kaiser Permanente Southern California experience. Med Care Res Rev 2013; 70:330-45.
7. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 2012; 16:37-41.
8. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305:160-6.
9. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25:8326-37.
10. Tseng HF, Schmid DS, Harpaz R, et al. Assessment of the accuracy of clinical diagnosis of herpes zoster by polymerase chain reaction. Presented at: IDWeek, San Francisco, California, 2013.
11. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A populationbased study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341-9.
12. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005; 133:245-53.
13. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191:2002-7.
14. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605-9.
15. Tseng HF, Lewin B, Hales CM, et al. Zoster vaccine and the risk of postherpetic neuralgia in patients who developed herpes zoster despite having received the zoster vaccine. J Infect Dis 2015; 212:1222-31. BRIEF